MedTrace Logo

Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)

NCT01612884 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 67

Last updated 2018-04-26

Study results available
· View outcomes & findings →

Summary

Personalized treatment approaches and antiplatelet drug choice have been proposed to optimize safety of coronary stenting by reducing heart attacks and repeat interventions while simultaneously minimizing adverse bleeding events. This study compares the efficacy of two laboratory guided treatment algorithms to personalize antiplatelet medication choice after coronary stenting

Conditions

Interventions

DRUG

Prasugrel

Prasugrel 60mg loading dose at time of PCI if clopidogrel non-responder

DRUG

Clopidogrel

Clopidogrel 300mg loading dose at time of PCI if clopidogrel responder

Sponsors & Collaborators

  • Indiana University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2017-03-31
Completion
2017-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01612884 on ClinicalTrials.gov